Abivax (ABVX) said Thursday that it reached 82% of target enrollment in a phase 3 trial evaluating obefazimod for the treatment of moderately to severely active ulcerative colitis.

Enrollment stood at 1,003 of 1,224 targeted participants and is expected to be completed in Q2, according to the biotechnology company.

The company's cash runway will extend beyond the trial readout and into Q4, Abivax said.

Price: 6.68, Change: -0.30, Percent Change: -4.30